Cargando…
P006: Clinical outcome of classical Hodgkin Lymphoma patients receiving systemic anti-lymphoma treatment during SARS-COV-2 positivity: Results from the chemo-covid study on behalf of fondazione italiana linfomi
| Autores principales: | , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621568/ http://dx.doi.org/10.1097/01.HS9.0000890592.58331.aa |
| _version_ | 1784821587718963200 |
|---|---|
| author | Rusconi, Chiara Puccini, Benedetta Visco, Carlo Ricci, Francesca Re, Alessandro Zilioli, Vittorio R. Zerbi, Caterina Hohaus, Stefan Mazzon, Federico Ciceri, Manuel Guidetti, Anna Marasco, Vincenzo Rigacci, Luigi |
| author_facet | Rusconi, Chiara Puccini, Benedetta Visco, Carlo Ricci, Francesca Re, Alessandro Zilioli, Vittorio R. Zerbi, Caterina Hohaus, Stefan Mazzon, Federico Ciceri, Manuel Guidetti, Anna Marasco, Vincenzo Rigacci, Luigi |
| author_sort | Rusconi, Chiara |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9621568 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-96215682022-11-01 P006: Clinical outcome of classical Hodgkin Lymphoma patients receiving systemic anti-lymphoma treatment during SARS-COV-2 positivity: Results from the chemo-covid study on behalf of fondazione italiana linfomi Rusconi, Chiara Puccini, Benedetta Visco, Carlo Ricci, Francesca Re, Alessandro Zilioli, Vittorio R. Zerbi, Caterina Hohaus, Stefan Mazzon, Federico Ciceri, Manuel Guidetti, Anna Marasco, Vincenzo Rigacci, Luigi Hemasphere Advanced Stages Lippincott Williams & Wilkins 2022-10-03 /pmc/articles/PMC9621568/ http://dx.doi.org/10.1097/01.HS9.0000890592.58331.aa Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Advanced Stages Rusconi, Chiara Puccini, Benedetta Visco, Carlo Ricci, Francesca Re, Alessandro Zilioli, Vittorio R. Zerbi, Caterina Hohaus, Stefan Mazzon, Federico Ciceri, Manuel Guidetti, Anna Marasco, Vincenzo Rigacci, Luigi P006: Clinical outcome of classical Hodgkin Lymphoma patients receiving systemic anti-lymphoma treatment during SARS-COV-2 positivity: Results from the chemo-covid study on behalf of fondazione italiana linfomi |
| title | P006: Clinical outcome of classical Hodgkin Lymphoma patients receiving systemic anti-lymphoma treatment during SARS-COV-2 positivity: Results from the chemo-covid study on behalf of fondazione italiana linfomi |
| title_full | P006: Clinical outcome of classical Hodgkin Lymphoma patients receiving systemic anti-lymphoma treatment during SARS-COV-2 positivity: Results from the chemo-covid study on behalf of fondazione italiana linfomi |
| title_fullStr | P006: Clinical outcome of classical Hodgkin Lymphoma patients receiving systemic anti-lymphoma treatment during SARS-COV-2 positivity: Results from the chemo-covid study on behalf of fondazione italiana linfomi |
| title_full_unstemmed | P006: Clinical outcome of classical Hodgkin Lymphoma patients receiving systemic anti-lymphoma treatment during SARS-COV-2 positivity: Results from the chemo-covid study on behalf of fondazione italiana linfomi |
| title_short | P006: Clinical outcome of classical Hodgkin Lymphoma patients receiving systemic anti-lymphoma treatment during SARS-COV-2 positivity: Results from the chemo-covid study on behalf of fondazione italiana linfomi |
| title_sort | p006: clinical outcome of classical hodgkin lymphoma patients receiving systemic anti-lymphoma treatment during sars-cov-2 positivity: results from the chemo-covid study on behalf of fondazione italiana linfomi |
| topic | Advanced Stages |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621568/ http://dx.doi.org/10.1097/01.HS9.0000890592.58331.aa |
| work_keys_str_mv | AT rusconichiara p006clinicaloutcomeofclassicalhodgkinlymphomapatientsreceivingsystemicantilymphomatreatmentduringsarscov2positivityresultsfromthechemocovidstudyonbehalfoffondazioneitalianalinfomi AT puccinibenedetta p006clinicaloutcomeofclassicalhodgkinlymphomapatientsreceivingsystemicantilymphomatreatmentduringsarscov2positivityresultsfromthechemocovidstudyonbehalfoffondazioneitalianalinfomi AT viscocarlo p006clinicaloutcomeofclassicalhodgkinlymphomapatientsreceivingsystemicantilymphomatreatmentduringsarscov2positivityresultsfromthechemocovidstudyonbehalfoffondazioneitalianalinfomi AT riccifrancesca p006clinicaloutcomeofclassicalhodgkinlymphomapatientsreceivingsystemicantilymphomatreatmentduringsarscov2positivityresultsfromthechemocovidstudyonbehalfoffondazioneitalianalinfomi AT realessandro p006clinicaloutcomeofclassicalhodgkinlymphomapatientsreceivingsystemicantilymphomatreatmentduringsarscov2positivityresultsfromthechemocovidstudyonbehalfoffondazioneitalianalinfomi AT ziliolivittorior p006clinicaloutcomeofclassicalhodgkinlymphomapatientsreceivingsystemicantilymphomatreatmentduringsarscov2positivityresultsfromthechemocovidstudyonbehalfoffondazioneitalianalinfomi AT zerbicaterina p006clinicaloutcomeofclassicalhodgkinlymphomapatientsreceivingsystemicantilymphomatreatmentduringsarscov2positivityresultsfromthechemocovidstudyonbehalfoffondazioneitalianalinfomi AT hohausstefan p006clinicaloutcomeofclassicalhodgkinlymphomapatientsreceivingsystemicantilymphomatreatmentduringsarscov2positivityresultsfromthechemocovidstudyonbehalfoffondazioneitalianalinfomi AT mazzonfederico p006clinicaloutcomeofclassicalhodgkinlymphomapatientsreceivingsystemicantilymphomatreatmentduringsarscov2positivityresultsfromthechemocovidstudyonbehalfoffondazioneitalianalinfomi AT cicerimanuel p006clinicaloutcomeofclassicalhodgkinlymphomapatientsreceivingsystemicantilymphomatreatmentduringsarscov2positivityresultsfromthechemocovidstudyonbehalfoffondazioneitalianalinfomi AT guidettianna p006clinicaloutcomeofclassicalhodgkinlymphomapatientsreceivingsystemicantilymphomatreatmentduringsarscov2positivityresultsfromthechemocovidstudyonbehalfoffondazioneitalianalinfomi AT marascovincenzo p006clinicaloutcomeofclassicalhodgkinlymphomapatientsreceivingsystemicantilymphomatreatmentduringsarscov2positivityresultsfromthechemocovidstudyonbehalfoffondazioneitalianalinfomi AT rigacciluigi p006clinicaloutcomeofclassicalhodgkinlymphomapatientsreceivingsystemicantilymphomatreatmentduringsarscov2positivityresultsfromthechemocovidstudyonbehalfoffondazioneitalianalinfomi |